For a professional athlete, the most grueling part of an injury is rarely the physical pain; it is the uncertainty of the timeline. For Loïs Boisson, the silence that has followed her last competitive match is not merely a result of a recovering body, but of a systemic deadlock between her coaching ambitions and the medical bureaucracy of French tennis.
The French player recently confirmed the end of her professional relationship with Spanish coach Carlos Martinez. Although coaching changes are a staple of the WTA Tour, this separation is less a reflection of a failed partnership and more a symptom of a deeper, more frustrating conflict regarding Boisson’s health and her path back to the court.
The collaboration between the Dijon native and the 51-year-vintage Martinez was brief, characterized more by its potential than its execution. The pair accompanied one another on the circuit only once, during the Beijing tournament last September. Boisson showed flashes of the form that has made her a rising prospect in France, reaching the third round before falling to American Emma Navarro. Since that exit in China, Boisson has not played a single professional match.
A Dispute Beyond the Baseline
To the casual observer, a coach parting ways with a player after a few months suggests a lack of chemistry. However, the reality is that the partnership never truly had the chance to evolve. The friction, according to those close to the situation, is not between player and coach, but between the coaching staff and the medical establishment.
Sarah Pitkowski, the communications director for the Fédération Française de Tennis (FFT), indicated that the split from Martinez is a secondary issue. The primary obstacle is a fundamental disagreement regarding the medical diagnosis of Boisson’s injury and the subsequent recovery protocol managed by the FFT medical service.
When a player is under the wing of a national federation, the medical team often holds the final say on “return-to-play” clearances. When a private coach or a player’s personal medical team disagrees with that diagnosis, the result is often a stalemate. For Boisson, this disagreement has stalled her momentum at a critical juncture in her career.
The Race for the Clay Season
The timing of this medical impasse is particularly precarious. Boisson had targeted several returns to competition during the first quarter of the year, but those plans failed to materialize. The focus has now shifted toward the clay court season, a surface where the French player traditionally finds her rhythm.
The stakes are high. Boisson has significant ranking points to defend, most notably at Roland-Garros. In the volatile ecosystem of the WTA rankings, a prolonged absence can be devastating, stripping a player of their seeding and forcing them to grind through qualifying rounds just to enter the main draw of the tournaments they once dominated.
Timeline of Absence and Recovery
| Period | Status/Event | Outcome/Detail |
|---|---|---|
| September 2024 | Beijing Tournament | Reached 3rd Round; lost to Emma Navarro |
| Oct 2024 – March 2025 | Inactive | Injury recovery and medical disputes |
| Q1 2025 | Planned Returns | Cancelled due to diagnosis disagreements |
| Spring 2025 | Target Return | Clay court season / Roland-Garros |
The Human Cost of Medical Deadlocks
For a player like Boisson, who carries the hopes of the Dijon tennis community, these disputes are more than just administrative hurdles. They represent a psychological battle. The transition from the high of a third-round run in Beijing to the isolation of a medical dispute can be jarring. The sport of tennis is an individualistic pursuit, but the infrastructure supporting it—federations, medical boards, and coaching carousels—is a complex web that can sometimes trap the athlete in the middle.
The disagreement with the FFT medical service highlights a recurring tension in modern sport: the balance between the conservative approach of federation doctors, who prioritize long-term health and liability, and the urgency of the athlete and coach, who prioritize the competitive window.
Disclaimer: This article discusses medical disagreements and sports injuries for informational purposes and does not constitute medical advice.
The immediate future for Boisson depends on whether a compromise can be reached between her team and the FFT medical staff. The next critical checkpoint will be the official entry lists for the early clay court events, which will signal whether she has finally received the medical clearance necessary to step back onto the court. Until then, the French talent remains in a state of forced hibernation, waiting for the bureaucracy to align with her ambition.
We want to hear from you. Should national federations have the final say in a player’s medical diagnosis, or should the athlete’s private team take precedence? Share your thoughts in the comments below.
